H. Lundbeck A/S- (NASDAQ:HLUYY) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued on Wednesday.
According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “
Separately, Deutsche Bank AG downgraded shares of H. Lundbeck A/S- from a “hold” rating to a “sell” rating in a research report on Friday, July 28th.
H. Lundbeck A/S- (HLUYY) opened at 62.55 on Wednesday. The stock has a market cap of $12.34 billion and a PE ratio of 38.44. H. Lundbeck A/S- has a 12-month low of $31.64 and a 12-month high of $66.67. The firm has a 50 day moving average of $60.46 and a 200-day moving average of $55.44.
ILLEGAL ACTIVITY NOTICE: This report was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://stocknewstimes.com/2017/10/11/h-lundbeck-as-hluyy-rating-lowered-to-hold-at-zacks-investment-research.html.
H. Lundbeck A/S- Company Profile
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.
Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.